Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by John G Ullman & Associates Inc.

Key Points

• John G Ullman & Associates Inc. reduced its holdings in Regeneron Pharmaceuticals by 78.1%, selling 5,025 shares and retaining 1,405 shares valued at approximately $738,000.
• Regeneron Pharmaceuticals reported $12.89 earnings per share (EPS) for the last quarter, significantly surpassing the consensus estimate of $8.43, with revenue of $3.68 billion.
• The company announced a quarterly dividend of $0.88 per share, reflecting a payout ratio of 8.87% and an annualized yield of 0.6%.

John G Ullman & Associates Inc. lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 78.1% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,405 shares of the biopharmaceutical company's stock after selling 5,025 shares during the quarter. John G Ullman & Associates Inc.'s holdings in Regeneron Pharmaceuticals were worth $738,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of REGN. Nuveen LLC bought a new position in Regeneron Pharmaceuticals during the 1st quarter worth approximately $343,764,000. Pacer Advisors Inc. lifted its holdings in Regeneron Pharmaceuticals by 2,296.9% during the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock worth $258,366,000 after buying an additional 390,374 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Regeneron Pharmaceuticals by 18.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock worth $724,984,000 after buying an additional 174,056 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock worth $5,966,767,000 after buying an additional 121,545 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Regeneron Pharmaceuticals by 4.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company's stock worth $1,379,467,000 after buying an additional 89,579 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Up 1.6%

Shares of NASDAQ REGN opened at $578.05 on Friday. The company has a market cap of $61.27 billion, a price-to-earnings ratio of 14.57, a price-to-earnings-growth ratio of 1.80 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,002.69. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The stock's 50 day simple moving average is $574.64 and its 200 day simple moving average is $562.46.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter last year, the business posted $11.56 EPS. The business's revenue was up 3.6% on a year-over-year basis. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is presently 8.87%.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Jefferies Financial Group increased their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a report on Wednesday, August 27th. Raymond James Financial raised Regeneron Pharmaceuticals to a "moderate buy" rating in a report on Tuesday, September 2nd. Canaccord Genuity Group reaffirmed a "buy" rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, October 14th. UBS Group reaffirmed a "neutral" rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Finally, Truist Financial cut their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Three analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $817.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.